Latest news with #MassiveBio
Business Wire
3 days ago
- Business
- Business Wire
Massive Bio Recognized in Two Key Categories on CB Insights' AI Drug Research & Development Market Map
CHICAGO--(BUSINESS WIRE)--Massive Bio, a leader in AI-powered oncology patient recruitment and clinical trial matching, has been named in two pivotal categories on CB Insights' latest AI Drug Research & Development Market Map. This recognition underscores Massive Bio's innovative contributions to revolutionizing cancer care through advanced artificial intelligence solutions. "Being recognized in two critical categories by CB Insights is a testament to the power of AI in transforming oncology care." Share CB Insights' market map highlights companies at the forefront of leveraging AI to accelerate drug discovery and development. Massive Bio's inclusion in both the 'Clinical Trial Matching' and 'Patient Recruitment' categories reflects its dual impact on streamlining clinical trial processes and enhancing patient access to cutting-edge therapies. 'Being recognized by CB Insights in two critical categories is a testament to our team's dedication to transforming oncology care,' said Selin Kurnaz, PhD, CEO and Co-Founder of Massive Bio. 'Our AI-driven platform is designed to bridge the gap between patients and clinical trials, ensuring that individuals receive the most appropriate and timely treatments available.' Arturo Loaiza-Bonilla, MD, Co-Founder and Chief Medical Officer, added, 'This acknowledgment validates our commitment to integrating advanced AI technologies into clinical workflows. By optimizing trial matching and patient recruitment, we're not only improving operational efficiencies but also enhancing patient outcomes in oncology.' This recognition from CB Insights follows a milestone presence at ASCO25, where Arturo Loaiza-Bonilla presented a poster session on AI-powered clinical trial matching and participated in the ASCO/ESMO Joint Session, emphasizing international collaboration in oncology innovation. In addition, Selin Kurnaz was named a PCC Wayfinder, honoring her leadership in advancing equitable access and data-driven transformation in cancer care. Massive Bio's platform utilizes sophisticated algorithms and real-time data analytics to match cancer patients with suitable clinical trials, considering factors such as genetic profiles, treatment histories, and geographic locations. This approach has significantly increased trial enrollment rates and reduced the time required to identify eligible participants. The company's dual recognition by CB Insights highlights its comprehensive approach to addressing challenges in clinical trial enrollment and patient engagement. As the demand for personalized cancer treatments grows, Massive Bio continues to lead in providing scalable, AI-driven solutions that connect patients with life-saving clinical trials. About Massive Bio Massive Bio, co-founded by , Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit
Business Wire
30-05-2025
- Business
- Business Wire
Massive Bio to Showcase AI-Driven Oncology Innovations at ASCO25
CHICAGO--(BUSINESS WIRE)--Massive Bio, a global company specializing in AI-powered clinical trial matching and oncology data solutions, is participating in the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 30 to June 3 at McCormick Place in Chicago, Illinois. The company is exhibiting at Booth IH04 in the Innovation Hub, where its team is presenting its technology platform and initiatives to support clinical trial enrollment and data-driven decision-making in oncology. "Technology has matured to a point where it can meet patients at the right time, with the right opportunity, no matter how complex the diagnosis" Dr. Arturo Loaiza-Bonilla Share Massive Bio's participation reflects its commitment to expanding access to clinical research through digital innovation and real-world data. "At Massive Bio, we've always believed that access to clinical trials should not depend on geography, income, or system navigation," said Selin Kurnaz, Co-founder and Chief Executive Officer of Massive Bio. "ASCO25 is more than a conference. It's where meaningful partnerships are formed and shared challenges are addressed. We're honored to stand among those pushing the boundaries of what's possible for cancer patients worldwide." Selin Kurnaz will be participating in the PCC Drop-In Session at ASCO on May 30, 2025. This event brings together key stakeholders in precision oncology to discuss advancements in comprehensive genomic profiling, clinical trial matching, and patient-centered care. "ASCO is where science, technology, and care delivery converge," said Ç ağatay Çulcuoğlu, Co-founder, Chief Technology Officer and Chief Operating Officer of Massive Bio. "We're bringing not just advanced technology, but a vision for a more connected and intelligent ecosystem. One where data informs better decisions and every patient has a fair chance to engage in research." Scientific Contributions by Dr. Arturo Loaiza-Bonilla Massive Bio's Co-founder and Chief Medical Officer, Dr. Arturo Loaiza-Bonilla, is delivering two presentations at ASCO25: Poster Presentation Title: Transforming oncology clinical trial matching through multi-agent AI and an oncology-specific knowledge graph: A prospective evaluation in 3,800 patients Track: Care Delivery / Models of Care Abstract: 1554 | Poster Board: 320 Oral Presentation (ASCO/ESMO Joint Session) Title: Advancing Cancer Research and Patient-Centric Pre-Screening Hubs—Leveraging Digital Technologies Date and Time: June 1, 2025, 1:31 to 1:43 PM CDT Dr. Loaiza-Bonilla is also co-author of a recent NEJM AI article titled 'Harnessing Moravec's Paradox in Health Care: A New Era of Collaborative Intelligence,' which explores the role of AI in improving research workflows and enabling patient-centric trial access. "Technology has matured to a point where it can meet patients at the right time, with the right opportunity, no matter how complex the diagnosis," said Dr. Arturo Loaiza-Bonilla, Co-founder and Chief Medical Officer. "At ASCO25, we're proud to share how real-world data, artificial intelligence, and clinical expertise are coming together to break longstanding barriers in oncology research." Highlights at Booth IH04 ASCO25 attendees visiting Massive Bio's booth can: View demonstrations of the company's AI-driven clinical trial matching platform Learn more about DUO, a real-world data solution for healthcare analytics and provider engagement Meet with the clinical and commercial teams to explore collaboration opportunities Meetings can be scheduled in advance at About Massive Bio Massive Bio, co-founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit
Yahoo
14-04-2025
- Business
- Yahoo
Massive Bio Receives CNIL Certification for GDPR Compliance
BOCA RATON, Fla., April 14, 2025--(BUSINESS WIRE)--Massive Bio holds certification from the French Data Protection Authority (CNIL), confirming its compliance with the General Data Protection Regulation (GDPR) and French data privacy laws. This approval allows Massive Bio to securely process patient medical records (MRs) in France via its cloud-based platforms. This certification comes at a pivotal moment for France's healthcare system, as the country intensifies its investments in artificial intelligence. With €109 billion in AI funding announced in early 2025 and mandatory AI training for healthcare students launching nationwide, France is positioning itself as a European leader in ethical medical innovation¹ ². Massive Bio's AI-powered platform for clinical trial matching aligns with these national efforts to modernize care delivery and improve patient access to cutting-edge research opportunities. The company's compliance with CNIL requirements strengthens its ability to collaborate with healthcare institutions across France. "Our CNIL certification reaffirms that Massive Bio meets all regulatory standards for processing health data in France," said Çağatay Çulcuoğlu, Co-founder, CTO & COO of Massive Bio. "There are no legal obstacles preventing hospitals and physicians from securely sharing medical records with Massive Bio for clinical trial matching." "Through CNIL certification, we are expanding our footprint in France by leveraging institutional agreements," added Mert Sari, Director, OUS Provider Engagement at Massive Bio. "We are pleased to be the choice of patients and providers in France and remain committed to advancing our growth in the country as well as across Europe." Why This Matters As France accelerates AI integration in areas like precision oncology and health data infrastructure, certified platforms like Massive Bio play a key role in supporting this transition—bridging technology, regulation, and real-world patient impact³. About Massive Bio Massive Bio, co-founded by Selin Kurnaz, Arturo Loaiza-Bonilla, and Çağatay Çulcuoğlu, transforms the pharmaceutical value chain with AI-driven solutions. As an AI-enabled real-world data company, it streamlines the patient journey, enhances access to advanced treatment options, and optimizes clinical trials. Massive Bio collaborates with pharmaceutical companies, research organizations, and healthcare institutions worldwide. A founding member of the CancerX public-private partnership and participant in the Cancer Moonshot White House initiative, the company has received recognition from the National Cancer Institute and operates across 17 countries with a global team of over 100 employees. For more information, visit ___________________________________Sources¹ France Bets on Medical AI, to Train 100,000 Doctors Yearly – Medscapehttps:// ² Macron Announces $112B in AI Investment Over Coming Years – ³ France Takes Up the Medical AI Torch – MedTech Pulsehttps:// View source version on Contacts Massive BioMert TurkkanMarketing Director+1 646 461 4946pr@ Sign in to access your portfolio
